Has Mark Melamed, MD received payments from drug or device companies?

Yes. Drug and device makers reported $232 in general payments to Mark Melamed, MD across 10 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Melamed, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Melamed, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Melamed, MD

Ophthalmology · Hewlett, NYNPI 1952362261

Payments from drug & device makers

$232in general payments, 2019–2025

Across 10 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Mallinckrodt Hospital Products Inc.$122
Oyster Point Pharma, Inc.$67
Tarsus Pharmaceuticals, Inc.$43

What the payments were for

Food & beverage$232100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Mallinckrodt Hospital Products Inc.	4	$122
Oyster Point Pharma, Inc.	4	$67
Tarsus Pharmaceuticals, Inc.	2	$43

How this compares

$232 in reported general payments places this provider in the 20th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York →

Medicare billing

Part B allowed, 2024

$468,120

Medicare patients

1,616

Services billed

6,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RestasisCyclosporine	23	$22,624
Tobramycin-DexamethasoneTobramycin/Dexamethasone	396	$17,901
Cyclosporine	25	$10,285
XiidraLifitegrast	13	$10,057
LumiganBimatoprost	11	$6,842
Timolol Maleate	47	$4,593
Prednisolone Acetate	161	$4,374
RhopressaNetarsudil Mesylate	13	$4,037
Fluorometholone	31	$2,989
Latanoprost	359	$2,628
Ketorolac Tromethamine	87	$1,895
Brimonidine Tartrate	33	$1,825
MoxifloxacinMoxifloxacin Hcl	88	$1,768
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	126	$1,346
Pilocarpine Hcl	11	$623

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Hewlett

Douglas JabsNew York$24.3M
David RubaltelliBrooklyn$8.9M
Philip FerroneGreat Neck$5.8M
Eric DonnenfeldGarden City$2.6M
Nathan RadcliffeNew York$2.4M
Glenn StollerRockville Centre$2.1M
Richard SpaideNew York$1.7M
Paul HartmanRochester$1.6M
Jason SlakterNew York$1.2M
David ChuNew York$1.2M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →